Settlement Reached in Revance Therapeutics Securities Litigation Case Involving $17 Million Fund
On May 8, 2026, Entwistle & Cappucci LLP and Saxena White P.A. jointly announced a significant development in the legal realm concerning Revance Therapeutics, Inc. The United States District Court for the Middle District of Tennessee has proposed a settlement regarding the ongoing securities litigation involving Revance. The litigation, officially termed 'In Re Revance Therapeutics, Inc. Securities Litigation', has been ongoing for an extended period, and this newly proposed settlement could bring resolution to affected investors.
The proposed settlement amounts to an impressive $17 million. This substantial fund aims to compensate those who purchased or acquired Revance securities, specifically common stock under CUSIP 761330109 and 1.75% convertible senior unsecured notes under CUSIP 761330AB5. The eligible period for this settlement spans from February 29, 2024, through to the conclusion of Revance's merger transaction with Crown Laboratories, Inc., which occurred on February 6, 2025.
Investors within the defined time frame who believe they have been affected by this lawsuit may be entitled to a share of the net settlement fund. However, it is crucial for these individuals to understand that certain exclusions apply, as detailed within the stipulation of settlement provided for the court's review.
A key upcoming event related to this settlement is a scheduled court hearing set for August 10, 2026. Presided over by the Honorable Judge Eli J. Richardson, this hearing will address crucial matters such as the potential certification of the proposed class for settlement purposes. Additionally, it will ascertain whether the court deems the proposed settlement fair, reasonable, and adequate, as well as evaluate the proposed plan for allocating the settlement proceeds among the claimants.
The court’s evaluation will also consider an application for payment of attorneys' fees from the settlement fund along with any applicable awards for lead plaintiffs in this matter. All involved parties are urged to monitor these proceedings closely, as the outcomes will determine the settlement distribution and the litigation’s conclusion.
For individuals who identify as members of the settlement class, there are several critical actions to be aware of. To be eligible for a share of the settlement, affected parties must submit a Proof of Claim by mail, postmarked no later than August 28, 2026, or file online within the same timeframe. Failure to submit a valid claim will result in ineligibility for the distribution of funds; however, claimants will still be bound by any subsequent judgments from the court.
Should an investor choose to opt out of the settlement class entirely, it is essential that they submit a written request for exclusion, ensuring receipt by July 13, 2026. Exclusion from the settlement class means foregoing the ability to recover any funds through this settlement.
If any member of the settlement class has objections regarding the proposed class, the settlement terms, or the specified allocation plan, they have the right to file such objections with the court by the same deadline of July 13, 2026. However, it should be noted that individuals cannot petition for a different settlement; the court is limited to approving or denying the current proposal.
This proposed settlement marks a pivotal development for all stakeholders involved in the Revance Therapeutics litigation. As the hearing date approaches, it becomes essential for potential claimants to remain informed and proactive in understanding their rights and the steps necessary to participate in this settlement.
For further details, stakeholders are encouraged to visit the official settlement website at www.RevanceSecuritiesSettlement.com or reach out to the claims administrator at the provided contact information. With substantial monetary implications at stake, the conclusion of this litigation will signify both a financial resolution and a significant moment in securities law involving Revance Therapeutics.
Settlement Overview
The proposed settlement amounts to an impressive $17 million. This substantial fund aims to compensate those who purchased or acquired Revance securities, specifically common stock under CUSIP 761330109 and 1.75% convertible senior unsecured notes under CUSIP 761330AB5. The eligible period for this settlement spans from February 29, 2024, through to the conclusion of Revance's merger transaction with Crown Laboratories, Inc., which occurred on February 6, 2025.
Investors within the defined time frame who believe they have been affected by this lawsuit may be entitled to a share of the net settlement fund. However, it is crucial for these individuals to understand that certain exclusions apply, as detailed within the stipulation of settlement provided for the court's review.
Court Hearing and Class Certification
A key upcoming event related to this settlement is a scheduled court hearing set for August 10, 2026. Presided over by the Honorable Judge Eli J. Richardson, this hearing will address crucial matters such as the potential certification of the proposed class for settlement purposes. Additionally, it will ascertain whether the court deems the proposed settlement fair, reasonable, and adequate, as well as evaluate the proposed plan for allocating the settlement proceeds among the claimants.
The court’s evaluation will also consider an application for payment of attorneys' fees from the settlement fund along with any applicable awards for lead plaintiffs in this matter. All involved parties are urged to monitor these proceedings closely, as the outcomes will determine the settlement distribution and the litigation’s conclusion.
Rights of Affected Investors
For individuals who identify as members of the settlement class, there are several critical actions to be aware of. To be eligible for a share of the settlement, affected parties must submit a Proof of Claim by mail, postmarked no later than August 28, 2026, or file online within the same timeframe. Failure to submit a valid claim will result in ineligibility for the distribution of funds; however, claimants will still be bound by any subsequent judgments from the court.
Should an investor choose to opt out of the settlement class entirely, it is essential that they submit a written request for exclusion, ensuring receipt by July 13, 2026. Exclusion from the settlement class means foregoing the ability to recover any funds through this settlement.
Filing Objections
If any member of the settlement class has objections regarding the proposed class, the settlement terms, or the specified allocation plan, they have the right to file such objections with the court by the same deadline of July 13, 2026. However, it should be noted that individuals cannot petition for a different settlement; the court is limited to approving or denying the current proposal.
Conclusion
This proposed settlement marks a pivotal development for all stakeholders involved in the Revance Therapeutics litigation. As the hearing date approaches, it becomes essential for potential claimants to remain informed and proactive in understanding their rights and the steps necessary to participate in this settlement.
For further details, stakeholders are encouraged to visit the official settlement website at www.RevanceSecuritiesSettlement.com or reach out to the claims administrator at the provided contact information. With substantial monetary implications at stake, the conclusion of this litigation will signify both a financial resolution and a significant moment in securities law involving Revance Therapeutics.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.